Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial.

McCarty JM, Lock MD, Bennett S, Hunt KM, Simon JK, Gurwith M.

Vaccine. 2019 Feb 13. pii: S0264-410X(19)30162-8. doi: 10.1016/j.vaccine.2019.01.077. [Epub ahead of print]

PMID:
30772070
2.

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL.

Biol Blood Marrow Transplant. 2018 Nov 10. pii: S1083-8791(18)30698-0. doi: 10.1016/j.bbmt.2018.11.004. [Epub ahead of print]

PMID:
30423480
3.

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors.

Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE.

Haematologica. 2018 Oct 31. pii: haematol.2018.200121. doi: 10.3324/haematol.2018.200121. [Epub ahead of print]

4.

Autologous stem-cell transplant for metastatic renal medullary carcinoma.

Carden MA, Perdahl-Wallace E, Greenberg J, McCarty JM.

Pediatr Blood Cancer. 2018 Sep;65(9):e27267. doi: 10.1002/pbc.27267. Epub 2018 Jun 1. No abstract available.

PMID:
29856525
5.

Pediatric Coccidioidomycosis: Case Series From a California Pediatric Infectious Diseases Clinic.

Lee LA, Sondermeyer Cooksey GL, Kim JJ, Kahal A, Gilliss D, Naeem F, McCarty JM, Vugia DJ.

Pediatr Infect Dis J. 2019 Feb;38(2):115-121. doi: 10.1097/INF.0000000000002069.

PMID:
29620721
6.

The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation.

Kobulnicky DJ, Sabo RT, Sharma S, Shubar Ali AS, Kobulnicky KM, Roberts CH, Clark WB, Chung HM, McCarty JM, Toor AA.

Leuk Lymphoma. 2018 Dec;59(12):2973-2981. doi: 10.1080/10428194.2018.1452216. Epub 2018 Apr 4.

PMID:
29616870
7.

Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.

Maples KT, Sabo RT, McCarty JM, Toor AA, Hawks KG.

Leuk Lymphoma. 2018 Dec;59(12):2836-2841. doi: 10.1080/10428194.2018.1443334. Epub 2018 Apr 4.

PMID:
29616863
8.

The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.

Andermann TM, Peled JU, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink MRM, Alousi A, Balderman S, Chiusolo P, Clark WB, Holler E, Howard A, Kean LS, Koh AY, McCarthy PL, McCarty JM, Mohty M, Nakamura R, Rezvani K, Segal BH, Shaw BE, Shpall EJ, Sung AD, Weber D, Whangbo J, Wingard JR, Wood WA, Perales MA, Jenq RR, Bhatt AS; Blood and Marrow Transplant Clinical Trials Network.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1322-1340. doi: 10.1016/j.bbmt.2018.02.009. Epub 2018 Feb 19. No abstract available.

PMID:
29471034
9.

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.

Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, Kaufman JL, McCarty JM, Vargo R, Cheverton PD, Struijs M, Bolwell B, DiPersio JF.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1187-1195. doi: 10.1016/j.bbmt.2018.01.039. Epub 2018 Feb 2.

10.

Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.

McCarty JM, Lock MD, Hunt KM, Simon JK, Gurwith M.

Vaccine. 2018 Feb 1;36(6):833-840. doi: 10.1016/j.vaccine.2017.12.062. Epub 2018 Jan 6.

11.

Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis.

Kalman NS, Mukhopadhyay ND, Roberts CH, Chung HM, Clark WB, McCarty JM, Toor AA, Song S.

Leuk Lymphoma. 2017 Dec;58(12):2983-2984. doi: 10.1080/10428194.2017.1321747. Epub 2017 May 31. No abstract available.

PMID:
28562151
12.

Treatment of acute fibrinous organizing pneumonia following hematopoietic cell transplantation with etanercept.

Simmons GL, Chung HM, McCarty JM, Toor AA, Farkas D, Miller K, Clark WB.

Bone Marrow Transplant. 2017 Jan;52(1):141-143. doi: 10.1038/bmt.2016.197. Epub 2016 Aug 15. No abstract available.

13.

Epidemiology of Pediatric Coccidioidomycosis in California, 2000-2012.

Sondermeyer GL, Lee LA, Gilliss D, McCarty JM, Vugia DJ.

Pediatr Infect Dis J. 2016 Feb;35(2):166-71. doi: 10.1097/INF.0000000000000952.

PMID:
26461228
14.

Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.

Curtis LM, Datiles MB 3rd, Steinberg SM, Mitchell SA, Bishop RJ, Cowen EW, Mays J, McCarty JM, Kuzmina Z, Pirsl F, Fowler DH, Gress RE, Pavletic SZ.

Haematologica. 2015 Sep;100(9):1228-36. doi: 10.3324/haematol.2015.124131. Epub 2015 Jun 18.

15.

Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes.

Toor AA, Sabo RT, Roberts CH, Moore BL, Salman SR, Scalora AF, Aziz MT, Shubar Ali AS, Hall CE, Meier J, Thorn RM, Wang E, Song S, Miller K, Rizzo K, Clark WB, McCarty JM, Chung HM, Manjili MH, Neale MC.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1237-45. doi: 10.1016/j.bbmt.2015.03.011. Epub 2015 Apr 4.

16.

Stem cell transplantation as a dynamical system: are clinical outcomes deterministic?

Toor AA, Kobulnicky JD, Salman S, Roberts CH, Jameson-Lee M, Meier J, Scalora A, Sheth N, Koparde V, Serrano M, Buck GA, Clark WB, McCarty JM, Chung HM, Manjili MH, Sabo RT, Neale MC.

Front Immunol. 2014 Dec 3;5:613. doi: 10.3389/fimmu.2014.00613. eCollection 2014. Review.

17.

Effectiveness and toxicity of high-dose cyclophosphamide in obese versus non-obese patients receiving allogeneic hematopoietic stem cell transplant.

Hunter MR, Sabo RT, McCarty JM, Newland AM.

J Oncol Pharm Pract. 2016 Feb;22(1):54-9. doi: 10.1177/1078155214549617. Epub 2014 Sep 22.

PMID:
25245037
18.

Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.

Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi S, McCarty JM, Gonzalez CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Wu J, Confer DL, Anasetti C.

J Clin Oncol. 2014 Aug 1;32(22):2365-72. doi: 10.1200/JCO.2013.54.4577. Epub 2014 Jun 30.

19.

Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).

Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA.

Haematologica. 2014 Jan;99(1):111-5. doi: 10.3324/haematol.2013.085811. Epub 2013 Sep 27.

20.

Pediatric coccidioidomycosis in central California: a retrospective case series.

McCarty JM, Demetral LC, Dabrowski L, Kahal AK, Bowser AM, Hahn JE.

Clin Infect Dis. 2013 Jun;56(11):1579-85. doi: 10.1093/cid/cit114. Epub 2013 Mar 5.

PMID:
23463637
21.

Treatment of pediatric refractory coccidioidomycosis with combination voriconazole and caspofungin: a retrospective case series.

Levy ER, McCarty JM, Shane AL, Weintrub PS.

Clin Infect Dis. 2013 Jun;56(11):1573-8. doi: 10.1093/cid/cit113. Epub 2013 Mar 5.

PMID:
23463636
22.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network.

N Engl J Med. 2012 Oct 18;367(16):1487-96. doi: 10.1056/NEJMoa1203517.

23.

Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.

Toor AA, Payne KK, Chung HM, Sabo RT, Hazlett AF, Kmieciak M, Sanford K, Williams DC, Clark WB, Roberts CH, McCarty JM, Manjili MH.

Br J Haematol. 2012 Sep;158(6):700-11. doi: 10.1111/j.1365-2141.2012.09225.x. Epub 2012 Jul 23.

24.

Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients.

Portier DA, Sabo RT, Roberts CH, Fletcher DS, Meier J, Clark WB, Neale MC, Manjili MH, McCarty JM, Chung HM, Toor AA.

Bone Marrow Transplant. 2012 Dec;47(12):1513-9. doi: 10.1038/bmt.2012.81. Epub 2012 May 14.

25.

Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, Horowitz MM, Nakamura R, Pulsipher MA, Difronzo NL, Confer DL, Eapen M, Anderlini P.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1007-11. doi: 10.1016/j.bbmt.2012.04.014. Epub 2012 Apr 27.

26.

Distinct oligoclonal T cells are associated with graft versus host disease after stem-cell transplantation.

Berrie JL, Kmieciak M, Sabo RT, Roberts CH, Idowu MO, Mallory K, Chung HM, McCarty JM, Borrelli CA, Detwiler MM, Kazim AL, Toor AA, Manjili MH.

Transplantation. 2012 May 15;93(9):949-57. doi: 10.1097/TP.0b013e3182497561.

PMID:
22377792
27.

Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.

Toor AA, Sabo RT, Chung HM, Roberts C, Manjili RH, Song S, Williams DC Jr, Edmiston W, Gatesman ML, Edwards RW, Ferreira-Gonzalez A, Clark WB, Neale MC, McCarty JM, Manjili MH.

Biol Blood Marrow Transplant. 2012 May;18(5):794-804. doi: 10.1016/j.bbmt.2011.10.011. Epub 2011 Oct 17.

28.

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.

Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, Calandra G.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1578-86. doi: 10.1016/j.bbmt.2009.08.005. Epub 2009 Oct 4.

29.

Improving stem cell mobilization strategies: future directions.

Bensinger W, DiPersio JF, McCarty JM.

Bone Marrow Transplant. 2009 Feb;43(3):181-95. doi: 10.1038/bmt.2008.410. Epub 2009 Jan 12. Review.

PMID:
19139734
30.

A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions.

McCarty JM, Melone PD, Simanis JP, Kanamori D, Dessypris EN, Warshamana-Greene GS.

Exp Hematol. 2006 Jan;34(1):87-96.

PMID:
16413395
31.

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G.

Blood. 2005 Sep 1;106(5):1867-74. Epub 2005 May 12.

32.

Transplant strategies for idiopathic myelofibrosis.

McCarty JM.

Semin Hematol. 2004 Apr;41(2 Suppl 3):23-9. Review.

PMID:
15190520
33.

Na+-H+ exchange activity in taste receptor cells.

Vinnikova AK, Alam RI, Malik SA, Ereso GL, Feldman GM, McCarty JM, Knepper MA, Heck GL, DeSimone JA, Lyall V.

J Neurophysiol. 2004 Mar;91(3):1297-313. Epub 2003 Nov 5.

34.

Comparison of azithromycin and cefadroxil for the treatment of uncomplicated skin and skin structure infections.

Jennings MB, McCarty JM, Scheffler NM, Puopolo AD, Rothermel CD.

Cutis. 2003 Sep;72(3):240-4.

PMID:
14533837
35.

Mycotic osteomyelitis due to Scedosporium Apiospermum: MR imaging-pathologic correlation.

Sydnor MK, Kaushik S, Knight TE Jr, Bridges CL, McCarty JM.

Skeletal Radiol. 2003 Nov;32(11):656-60. Epub 2003 Sep 23.

PMID:
14504834
36.

PEPCK mRNA localization in proximal tubule and gene regulation during metabolic acidosis.

Drewnowsk KD, Craig MR, Digiovanni SR, McCarty JM, Moorman AF, Lamers WH, Schoolwerth AC.

J Physiol Pharmacol. 2002 Mar;53(1):3-20.

37.

Granulomatous myositis: a manifestation of chronic graft-versus-host disease.

Kaushik S, Flagg E, Wise CM, Hadfield G, McCarty JM.

Skeletal Radiol. 2002 Apr;31(4):226-9. Epub 2002 Feb 20.

PMID:
11904691
38.
39.

Neuronal nitric oxide synthase: expression in rat parietal cells.

Premaratne S, Xue C, McCarty JM, Zaki M, McCuen RW, Johns RA, Schepp W, Neu B, Lippman R, Melone PD, Schubert ML.

Am J Physiol Gastrointest Liver Physiol. 2001 Feb;280(2):G308-13.

40.

Comparative safety and efficacy of cefdinir vs amoxicillin/clavulanate for treatment of suppurative acute otitis media in children.

Block SL, McCarty JM, Hedrick JA, Nemeth MA, Keyserling CH, Tack KJ; Cefdinir Otitis Media Study Group.

Pediatr Infect Dis J. 2000 Dec;19(12 Suppl):S159-65.

PMID:
11144398
41.

Clarithromycin in the management of community-acquired pneumonia.

McCarty JM.

Clin Ther. 2000 Mar;22(3):281-94; discussion 265. Review.

PMID:
10963284
42.
43.

Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: two phase II clinical studies.

Swinehart JM, Skinner RB, McCarty JM, Miller BH, Tyring SK, Korey A, Orenberg EK.

Genitourin Med. 1997 Dec;73(6):481-7.

44.

Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata. A phase 3 clinical study.

Swinehart JM, Sperling M, Phillips S, Kraus S, Gordon S, McCarty JM, Webster GF, Skinner R, Korey A, Orenberg EK.

Arch Dermatol. 1997 Jan;133(1):67-73.

PMID:
9006374
45.

Penetration of clarithromycin into middle ear fluid of children with acute otitis media.

Gan VN, McCarty JM, Chu SY, Carr R.

Pediatr Infect Dis J. 1997 Jan;16(1):39-43.

PMID:
9002099
46.

Azithromycin (zithromax).

McCarty JM.

Infect Dis Obstet Gynecol. 1996;4(4):215-20.

47.

Murine thrombopoietin mRNA levels are modulated by platelet count.

McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K.

Blood. 1995 Nov 15;86(10):3668-75.

48.

Interleukin-4 induces endothelial vascular cell adhesion molecule-1 (VCAM-1) by an NF-kappa b-independent mechanism.

McCarty JM, Yee EK, Deisher TA, Harlan JM, Kaushansky K.

FEBS Lett. 1995 Sep 25;372(2-3):194-8.

49.
50.

Thrombopoietin from human embryonic kidney cells is the same factor as c-mpl-ligand.

McDonald TP, Wendling F, Vainchenker W, McCarty JM, Jorgenson MJ, Kaushansky K.

Blood. 1995 Jan 1;85(1):292-4. No abstract available.

Supplemental Content

Loading ...
Support Center